About the Event
The Hepatitis B Virus (HBV) infects 270 million people globally and complications caused by HBV kill close to 1 million people per year.
Given the scope and urgency of the problem, Assembly Bio (NASDAQ: ASMB) has several programs in its pipeline for curing HBV. A triple combo trial is currently in Phase 2 and an a novel oral core inhibitor drug will enter clinical trials later this year.
The Assembly Bio team has over 80 years of experience in treating HCV, HIV, and HBV, andincludes Nobel Laureate, Sir Michael Houghton, PhD as a member of the board of directors.
Join our webinar to hear Assembly Bio President and CEO, Dr. John McHutchison discuss the company’s multi-platform approach to curing HBV and the major inflection points ahead this year and next.